Verastem Inc. is slashing its head count by 50%, or 20 employees, as the company continues to regroup after lead drug candidate VS-6063 failed to show an efficacy benefit for mesothelioma patients at an interim analysis in a Phase II clinical trial.
Boston-based Verastem isn't short on funds, since it had $132.1m in cash as of the end of the second quarter...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

